At a public workshop in Washington, the FDA convened researchers and clinicians to confront a quiet paradox: testosterone therapy is already woven into the lives of many menopausal women, yet the science meant to justify and guide that practice remains largely unwritten. No FDA-approved formulation exists for this use, no diagnostic threshold defines deficiency in women, and the long-term safety record is, by the agency's own admission, a blank page. The question being asked is not whether women deserve relief from the burdens of menopause, but whether medicine has earned the right to offer th